Filing Details

Accession Number:
0001213900-20-008792
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-07 19:27:40
Reporting Period:
2020-04-03
Accepted Time:
2020-04-07 19:27:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1658247 Crinetics Pharmaceuticals Inc. CRNX () 1231
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1618788 Vivo Capital Fund Viii, L.p. C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto, CA 94301
No No Yes No
1618789 Vivo Capital Viii, Llc C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto CA 94301
No No Yes No
1628048 Vivo Capital Surplus Fund Viii, L.p. C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto, CA 94301
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-04-03 263,600 $13.80 2,458,445 No 4 S Indirect See footnotes
Common Stock Disposition 2020-04-03 36,400 $13.80 339,480 No 4 S Indirect See footnotes
Common Stock Disposition 2020-04-07 5,373 $14.20 2,453,072 No 4 S Indirect See footnotes
Common Stock Disposition 2020-04-07 742 $14.20 338,738 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
Footnotes
  1. These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").
  2. These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").
  3. Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
  4. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0 to $15.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.